Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016–2021

Figures & data

Figure 1. PRISMA diagram.

Figure 2. Topics covered by the included papers. Individual studies could include more than one topic. PROs, patient-reported outcomes; PsA: psoriatic arthritis; PsO: psoriasis.

Figure 3. Median time to discontinuation for ixekizumab versus comparators in Blauvelt et al. 2020 (1) and Blauvelt et al. 2021 (2). *p < .001 vs IXE. ADA: adalimumab; All: all comparators; ETA: etanercept; IXE: ixekizumab; SEC: secukinumab; UST: ustekinumab.

Figure 4. Persistence rates of ixekizumab versus comparators in (A) the Corrona Registry (3); and (B) a retrospective study conducted by Torres and colleagues (4). BRO: brodalumab; GUS: guselkumab; IL: interleukin; IXE: ixekizumab; RIS: risankizumab; SEC: secukinumab; TNF: tumor necrosis factor; UST: ustekinumab.

Table 1. Comparative studies reporting PASI75/90/100 for ixekizumab in patients with psoriasis.

		TMT	Percentage of patients at 12 weeks				Percentage of patients at 24 weeks				Percentage of patients at 52 weeks
Study ID	Country		N	PASI 75	PASI 90	PASI 100	N	PASI 75	PASI 90	PASI 100	N	PASI 75	PASI 90	PASI 100
Caldarola et al. 2021 (1)	Italy	IXE	NR	63.4	52.9	49.6	NR	82.1	72.4	69.9	NR	NR	NR	NR
		SEC		83.6*	77.9*	74.6*		84.4	81.1	77.9
Georgakopoulos et al. 2020 (2)	Canada	IXE	60	75.0	NR	35.0	NR	NR	NR	NR	NR	NR	NR	NR
		SEC	60	76.7		25.0
		UST	60	73.3		30.0
Herrera-Acosta et al. 2020 (3)	Spain	IXE	NR	NR	NR	NR	NR	NR	NR	NR	29	75.9	62.1	41.4
		SEC									59	64.4	49.2	42.4
Herrera-Acosta et al. 2020 (4)	Spain	IXE	NR	NR	NR	NR	NR	NR	NR	NR	35	65.7	54.3	40.0
		UST									28	71.4	42.9	25.0
Pinter et al. 2020 (5)	Global	IXE	76	NR	65.8	42.1	NR	NR	NR	NR	NR	NR	NR	NR
		SEC	23		56.5	26.1
		GUS	35		20.0	11.4
		TIL	33		36.4	12.1
		ADA	28		53.6	17.9
		UST	10		0.0	0.0
Sherman et al. 2020 (6)	Israel	Anti-IL-17 exposed	62	77.5	47.5	27.5	45	74.3	54.9	19.4	29	66.6	54.1	20.8
		Anti-IL-17 naïve		81.9	72.7	40.9		64.3	64.3	35.7		80.0	60.0	40.0

*p < .001 vs ixekizumab. ADA: adalimumab; GUS: guselkumab; ID: identification; IL-17: interleukin-17; IXE: ixekizumab; NR: not reported; PASI: Psoriasis Area and Severity Index; SEC: secukinumab; TIL: tildrakizumab; TMT: treatment; UST: ustekinumab.

Table 2. Non-comparative studies reporting PASI75/90/100 for ixekizumab.

Study ID	Country	Percentage of patients at 12 weeks				Percentage of patients at 24 weeks				Percentage of patients at 52 weeks
		N	PASI 75	PASI 90	PASI 100	N	PASI 75	PASI 90	PASI 100	N	PASI 75	PASI 90	PASI 100
PsO
Briceño Casado et al. 2021 (7)	Spain	46	2	26	50	NR	NR	NR	NR	NR	NR	NR	NR
Chiricozzi et al. 2020 (8)	Italy	110	84.0	61.0	54.0	110	90.0	72.0	57.0	NR	NR	NR	NR
Conti et al. 2019 (9)^a	Italy	69	81.1	72.4	40.5	50	80.0	68.0	38.0	NR	NR	NR	NR
Damiani et al. 2019 (10)^b	Italy	47	NR	76.0	55.0	47^d	NR	78.0	57.9	NR	NR	NR	NR
		736/351^c		69.3	39.0	385^d		75.3	55.0
Deza et al. 2019 (11)	Spain	96	87.5	50.0	39.6	77	88.3	58.4	46.8	41	82.9	58.5	41.5
Georgakopoulos et al. 2019 (12))	Canada	60	75.0	NR	35.0	NR	NR	NR	NR	NR	NR	NR	NR
Georgakopoulos et al. 2019 (13)^a	Canada	31	71.0	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Gulliver et al. 2022 (14)	Canada	NR	NR	NR	NR	32	81.3^e	71.9^e	68.8^e	NR	NR	NR	NR
Magdaleno-Tapial et al. 2019 (15)	Spain	75	73.3^g	56.0^g	NR	67	74.6	62.7	NR	30	73.3	56.7	NR
Rivera et al. 2020 (16)	Spain	272	82.0	57.3	41.9	236	86.4	65.2	48.7	177	79.6	58.7	44.1
Sendin-Martín et al. 2020 (17)	Spain	NR	NR	67.7	NR	NR	NR	75.0	NR	NR	NR	69.2	NR
Sherman et al. 2019 (18)^a	Israel	17	76.5	52.9	29.4	15	73.3	53.3	33.3	4^g	75.0^g	25.0^g	25.0^g
PsA
Manfreda et al. 2020 (19)	Italy	NR	NR	NR	NR	26	84.6	80.8	57.7	17^f	82.4^g	70.6^g	64.7^g

^aPASI results measured following the switch to ixekizumab following secukinumab failure; ^bIndirect comparison made to UNCOVER studies: RCT results presented under IXE results; ^cN for PASI90/PASI100 at Week 12 in the RCT; ^dWeek 20 results; ^eResponders at Week 32; ^fWeek 16 results; ^gAt Week 48. ID, identification; IXE, ixekizumab; NR, not reported; PASI, Psoriasis Area and Severity Index; PGA, Physician Global Assessment; PsA, psoriatic arthritis; PsO, psoriasis; RCT, randomized controlled trial.

Di Meglio P, Villanova F, Nestle FO. Psoriasis. Cold Spring Harb Perspect Med. 2014; 14(8):a015354–a015354.

 PubMed Web of Science ®Google Scholar

Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63(4):278–285.

 PubMed Web of Science ®Google Scholar

Lima XT, Minnillo R, Spencer JM, et al. Psoriasis prevalence among the 2009 AAD national melanoma/skin cancer screening program participants. J Eur Acad Dermatol Venereol. 2013;27(6):680–685.

 PubMed Web of Science ®Google Scholar

Parisi R, Symmons DP, Griffiths CE, Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385.

 PubMed Web of Science ®Google Scholar

Lebwohl MG, Kavanaugh A, Armstrong AW, et al. US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the Population-Based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Am J Clin Dermatol. 2016;17(1):87–97.

 PubMed Web of Science ®Google Scholar

Ocampo DV, Gladman D. Psoriatic arthritis. F1000Res. 2019;8:1665.

 Google Scholar

Menter A. Psoriasis and psoriatic arthritis overview. Am J Manag Care. 2016;22(8 Suppl):S216–S24.

 PubMed Web of Science ®Google Scholar

Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251–265 e19.

 PubMed Web of Science ®Google Scholar

Kwan Z, Bong YB, Tan LL, et al. Determinants of quality of life and psychological status in adults with psoriasis. Arch Dermatol Res. 2018;310(5):443–451.

 PubMed Web of Science ®Google Scholar

Puig L, Thom H, Mollon P, et al. Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2017;31(2):213–220.

 PubMed Web of Science ®Google Scholar

Bulat V, Situm M, Delas Azdajic M, et al. Study on the impact of psoriasis on quality of life: psychological, social and financial implications. Psychiatr Danub. 2020;32(Suppl 4):553–561.

 PubMedGoogle Scholar

Husni ME. Comorbidities in psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):677–698.

 PubMed Web of Science ®Google Scholar

Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–551.

 PubMed Web of Science ®Google Scholar

Gordon KB, Blauvelt A, Papp KA, UNCOVER-3 Study Group, et al. Phase 3 trials of ixekizumab in moderate-to-Severe plaque psoriasis. N Engl J Med. 2016;375(4):345–356.

 PubMed Web of Science ®Google Scholar

Papp KA, Leonardi CL, Blauvelt A, et al. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). Br J Dermatol. 2018;178(3):674–681.

 PubMed Web of Science ®Google Scholar

Blauvelt A, Papp K, Gottlieb A, IXORA-R Study Group, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol. 2020;182(6):1348–1358.

 PubMed Web of Science ®Google Scholar

Blauvelt A, Leonardi C, Elewski B, IXORA-R Study Group, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol. 2021;184(6):1047–1058.

 PubMed Web of Science ®Google Scholar

Paul C, Griffiths CEM, van de Kerkhof PCM, et al. Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: results from IXORA-S, a phase 3 study. J Am Acad Dermatol. 2019;80(1):70–79 e3.

 PubMed Web of Science ®Google Scholar

Reich K, Pinter A, Lacour JP, IXORA-S investigators, et al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol. 2017;177(4):1014–1023.

 PubMed Web of Science ®Google Scholar

Data availability statement

Data sharing is not applicable to this article as no new data were created or analyzed in this study.